Skip to main content
main-content

Melanoma and skin cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews

‘Dramatically improved’ OS with checkpoint inhibitor use for melanoma brain metastases

Brain mets

Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.

medwireNews@ASCO2018

COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

medwireNews approvalsWatch

Adjuvant dabrafenib–trametinib approved for mutated melanoma

Drabrafenib

Find out more about this US FDA decision here

medwireNews podcast

SUMIT: Selumetinib in metastatic uveal melanoma

New Content Item (1)

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

01-11-2018 | Cancer immunotherapy | ESMO 2018 | News

Anti-PD-1 immunotherapy feasible for patients with HIV and cancer

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.

30-10-2018 | Melanoma | ESMO 2018 | News

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

18-10-2018 | Melanoma | News

Neoadjuvant checkpoint blockade investigated in high-risk melanoma

In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.

Practical management guides

01-02-2017 | Melanoma | Practical management guide | Collection

Cutaneous melanoma: A diagnostic guide

An illustrated step-by-step guide to diagnosing cutaneous melanoma.

Journal articles and book chapters

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

10-04-2018 | Response criteria | Article

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour L et al. Lancet Oncol 2017; 18(3): e143–e152. doi:10.1016/S1470-2045(17)30074-8

07-03-2018 | Cancer immunotherapy | Article

Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management

Samaan MA et al. Nat Rev Gastroenterol Hepatol 2018; 15:222–234. doi:10.1038/nrgastro.2018.1

06-03-2018 | Cancer immunotherapy | Article

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura et al. Nat Rev Clin Oncol 2018. doi:10.1038/nrclinonc.2018.29

16-02-2018 | Cancer immunotherapy | Article

Using immunotherapy to boost the abscopal effect

Ngwa W et al. Nat Rev Cancer 2018; 18: 313–322. doi:10.1038/nrc.2018.6

17-01-2018 | Melanoma | Article

Liquid biomarkers in melanoma: Detection and discovery

Lim SY et al. Mol Cancer 2018; 17:8. doi: 10.1186/s12943-018-0757-5

10-01-2018 | Melanoma | Article

Humanistic burden of disease for patients with advanced melanoma in Canada

Cheung WY et al. Support Care Cancer 2018. doi: 10.1007/s00520-017-4025-9

Reference

01-02-2017 | Cancer immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

image credits